Back to discover
Disease

Retinal vein occlusion

Late-stage therapeutic development

Also known as occlusion, of retinal vein.

17
Clinical trials
3
Associated genes
1
Related proteins
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Biosimilar medicine authorisation: Vislyfa (EMA)

Regulatory2026-07-15EMA

Biosimilar medicine authorisation: Eyluxvi (EMA)

Regulatory2025-09-15EMA

Biosimilar medicine authorisation: Afiveg (EMA)

Regulatory2025-08-18EMA

Biosimilar medicine authorisation: Mynzepli (EMA)

Regulatory2025-08-18EMA

Biosimilar medicine authorisation: Eiyzey (EMA)

Regulatory2025-08-14EMA

Biosimilar medicine authorisation: Vgenfli (EMA)

Regulatory2025-08-14EMA

Biosimilar medicine authorisation: Eydenzelt (EMA)

Regulatory2025-02-12EMA

Biosimilar medicine authorisation: Ahzantive (EMA)

Regulatory2025-01-13EMA

Biosimilar medicine authorisation: Baiama (EMA)

Regulatory2025-01-13EMA

Biosimilar medicine authorisation: Afqlir (EMA)

Regulatory2024-11-13EMA

Biosimilar medicine authorisation: Opuviz (EMA)

Regulatory2024-11-13EMA

Biosimilar medicine authorisation: Yesafili (EMA)

Regulatory2023-09-15EMA

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q2 2027.
  • 1 industry development reported.
Upcoming Milestones
Major developments
Major trial resultsHigh impact
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Results posted2026-06-17
Upcoming trial readoutHigh impact
A Phase 2 Randomized, Dose-Masked Study of Intravitreal EYE103 in Participants With Neovascular Age-Related Macular Degeneration (NVAMD) or Macular Edema Following Branch Retinal Vein Occlusion (BRVO)
Results expected Q2 20282026-09-04
Regulatory developmentWorth watching
Biosimilar approval — Ranibizumab
Vislyfa is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV)2026-07-15
Clinical Milestones6View
Results posted 1
Results expected 4
Recently completed 1
Industry & Market1View
Regulatory Updates1View
  • 2026-07-15Biosimilar approval — RanibizumabVislyfa is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV)
Activity timeline8

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Ranibizumabapproved

Biosimilar approval — Vislyfa is indicated in adults for: The treatment of neovascular (wet) age-related macul… (2026)

Afliberceptapproved

Biosimilar approval — Eyluxvi is indicated for adults for the treatment of- neovascular (wet) age-related macul… (2025)

Clinical trials

16 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
17
All trials
5
Active
15
Late-stage
6
Completed
Late-stage studies

Long-term Need of Ranibizumab Injections With or Without Early Targeted Peripheral Laser Photocoagulation for Treatment of Macular Edema Due to Central Retinal Vein Occlusion

Phase 3 · Active, not recruiting · University of Giessen

Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Treatment Retinal Vein Occlusion: a Double-blind Randomized Controlled Trial

Phase 4 · Recruiting · First Affiliated Hospital of Chongqing Medical University

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus PFS in Subjects With Visual Impairment Due to Retinal Disorders, NORSE SEVEN

Phase 3 · Active, not recruiting · Outlook Therapeutics, Inc.

Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion

Phase 3 · Completed · Bayer

A Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of 601 Versus Ranibizumab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Phase 3 · Completed · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion

Phase 4 · Completed · University of Athens
Recently completed

Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion

Phase 3 · Completed · Bayer

A Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of 601 Versus Ranibizumab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Phase 3 · Completed · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

Phase 3 · Completed · Hoffmann-La Roche

A Randomized Trial Comparing Treatment with Aflibercept and Ranibizuamab for Macular Edema After Branch Retinal Vein Occlusion

Phase 4 · Completed · St. Erik Eye Hospital

Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion

Phase 4 · Completed · University of Athens

Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.

Phase 3 · Completed · The Emmes Company, LLC

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

Product approvals and authorisations
2026emaBiosimilar approval — Ranibizumab· Vislyfa is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV) source ↗
2025emaBiosimilar approval — Aflibercept· Eyluxvi is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD) (see section 5.1),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),- visual impairment due to diabetic macular oedema (DME) (see section 5.1),- visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).  source ↗
2025emaBiosimilar approval — Aflibercept· Afiveg is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) (see section 1), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), visual impairment due to diabetic macular oedema (DME) (see section1), visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1). source ↗
2025emaBiosimilar approval — Aflibercept· Mynzepli is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO),- visual impairment due to diabetic macular oedema (DME),- visual impairment due to myopic choroidal neovascularisation (myopic CNV) source ↗
2025emaBiosimilar approval — Aflibercept· Eiyzey is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD) (see section 5.1),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),- visual impairment due to diabetic macular oedema (DME) (see section 5.1),- visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1)s. source ↗
2025emaBiosimilar approval — Aflibercept· Vgenfli is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO),- visual impairment due to diabetic macular oedema (DME),- visual impairment due to myopic choroidal neovascularisation (myopic CNV). source ↗
2025emaBiosimilar approval — Aflibercept· Eydenzelt is indicated for adults for the treatment of: neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), visual impairment due to diabetic macular oedema (DME) (see section 5.1), visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1). source ↗
2025emaBiosimilar approval — Aflibercept· Ahzantive is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), • visual impairment due to diabetic macular oedema (DME) (see section 5.1), • visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1). source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

3 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

PGF0.59VEGFB0.32PLCXD10.01

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Placenta growth factorvia PGF0.59

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Blockage of the RETINAL VEIN. Those at high risk for this condition include patients with HYPERTENSION; DIABETES MELLITUS; ATHEROSCLEROSIS; and other CARDIOVASCULAR DISEASES.

Synonyms

occlusion, of retinal vein

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.